Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Increased pressure within the pulmonary circulation due to lung or heart disorder.
Biomarker and diagnostic research for pulmonary hypertension has been reported in the published literature.
234 clinical trials registered, 61 recruiting. Interventions under study include other interventions, drug therapy, medical devices, and procedural interventions. Pipeline includes 7 PHASE4, 15 PHASE3, 24 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06573723](https://clinicaltrials.gov/study/NCT06573723) |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 6:00 AM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Institutional Registry of Rare Diseases |
— |
Hospital Italiano de Buenos Aires |
RECRUITING |
[NCT06409624](https://clinicaltrials.gov/study/NCT06409624) | Association Between Biomarkers and Kidney Function Decline in Pulmonary Hypertension | — | University of Giessen | RECRUITING |
[NCT06947460](https://clinicaltrials.gov/study/NCT06947460) | CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH | PHASE1 | Beijing GoBroad Hospital | RECRUITING |
[NCT05610631](https://clinicaltrials.gov/study/NCT05610631) | Pulmonary Hypertension Registry Switzerland | — | University of Zurich | RECRUITING |
[NCT07099144](https://clinicaltrials.gov/study/NCT07099144) | Inhaled Nitric Oxide for the Treatment of Neonatal Hypoxic Respiratory Failure With Pulmonary Hypertension | — | Lee's Pharmaceutical Limited | RECRUITING |
481 publications have been identified in PubMed for pulmonary hypertension. Research spans Review / Meta-Analysis (44%), Case Report / Case Series (20%), and Other (12%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 210 | 44% |
Patient case studies | 96 | 20% |
Other research | 59 | 12% |
Disease patterns and progression | 41 | 9% |
Laboratory research | 28 | 6% |
Testing and diagnosis research | 25 | 5% |
Clinical study results | 18 | 4% |
New treatment approaches | 4 | 1% |
Pagel PS (2026). [PMID: 41966907](https://pubmed.ncbi.nlm.nih.gov/41966907/). *J Cardiothorac Vasc Anesth*. [Review / Meta-Analysis]
Zhang P (2026). [PMID: 41541416](https://pubmed.ncbi.nlm.nih.gov/41541416/). *JHLT Open*. [Basic Science / Preclinical]
Diaz G (2026). [PMID: 42416589](https://pubmed.ncbi.nlm.nih.gov/42416589/). *Rev Cardiovasc Med*. [Review / Meta-Analysis]
Thès M (2026). [PMID: 42441215](https://pubmed.ncbi.nlm.nih.gov/42441215/). *JHLT Open*. [Epidemiology / Natural History]
Zhu R (2026). [PMID: 42107513](https://pubmed.ncbi.nlm.nih.gov/42107513/). *Curr Probl Cardiol*. [Review / Meta-Analysis]
Foroshani S (2026). [PMID: 38400720](https://pubmed.ncbi.nlm.nih.gov/38400720/). *Cardiol Rev*. [Review / Meta-Analysis]
Abdelhai OS (2026). [PMID: 41863531](https://pubmed.ncbi.nlm.nih.gov/41863531/). *JACC Case Rep*. [Case Report / Case Series]
Huang Z (2026). [PMID: 42479671](https://pubmed.ncbi.nlm.nih.gov/42479671/). *Cardiol Rev*. [Basic Science / Preclinical]
Zhu YJ (2026). [PMID: 41834753](https://pubmed.ncbi.nlm.nih.gov/41834753/). *Animal Model Exp Med*. [Review / Meta-Analysis]
Salvi M (2026). [PMID: 41240044](https://pubmed.ncbi.nlm.nih.gov/41240044/). *JACC Case Rep*. [Case Report / Case Series]
AI-curated news mentioning pulmonary hypertension
Updated Sep 18, 2026
A recent EUSTAR cohort study evaluates the effectiveness of oral anticoagulants in treating precapillary pulmonary hypertension linked to systemic sclerosis. The findings contribute to understanding treatment options for this rare condition.
A new study provides an updated etiological and clinical classification of pulmonary hypertension in children, enhancing understanding of this complex condition. This classification aims to improve diagnosis and treatment strategies for affected pediatric patients.
A new study explores the link between pulmonary hypertension and various genetic syndromes, expanding the understanding of this complex disease. The findings may inform future research and treatment strategies for patients with pulmonary hypertension associated with genetic conditions.
Roivant reports positive results from the Phase 2 PHocus trial of mosliciguat for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The study highlights the drug's potential in addressing significant unmet medical needs in this progressive condition.
David Ross continues to advocate for rare diseases, particularly pulmonary hypertension associated with interstitial lung disease (PH-ILD), two decades after losing his loved one. His advocacy highlights the ongoing need for compassion and dedication in supporting patients facing these challenges.